Atezolizumab

Elana Gotkine FRIDAY, June 9, 2023 (HealthDay News) -- For patients with locally advanced or metastatic renal cell carcinoma with disease progression on or after immune checkpoint inhibitor…

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab…

VB10.16 in combination with atezolizumab demonstrated an ORR of 21%, including 2 CRs and 6 PRs, in a heavily pre-treated population of patients with HPV16-positive advanced cervical cancer VB10.16 in combination with atezolizumab…

Nykode Therapeutics has reached the enrollment target of 50 patients in its VB C-02 trial for the treatment of advanced cervical cancerInterim efficacy and safety data expected in 1H 2022 OSLO, Norway, Feb. 11, 2022 (GLOBE NEWSWIRE) --…

HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the initiation of patient…

For previously treated patients with locally advanced or metastatic castration-resistant prostate cancer (CRPC), cabozantinib (Cabometyx) plus atezolizumab…

Use of atezolizumab (Tecentriq) as part of neoadjuvant therapy and again as maintenance met predetermined safety criteria for patients with resectable pleural…

Genentech announced that it will voluntarily withdraw its accelerated approval of the PD-L1 inhibitor atezolizumab (Tecentriq), in combination…

Adjuvant atezolizumab (Tecentriq) significantly improved disease-free survival (DFS) compared with best supportive care after chemotherapy in patients with…

Adding atezolizumab (Tecentriq) to standard of care treatment for patients with high-risk, HER2-positive early breast cancer did not improve…